Automated alerts sent to clinicians via patients' electronic health records (EHRs) identified patients with diagnosable acute kidney injury (AKI) who were taking one or more medications that could potentially further worsen their renal function. This led to a significant increase in discontinuations of the problematic drugs and better clinical outcomes in a subgroup of patients in a new multicenter, randomized study with more than 5000 participants.
- October 28, 2022
Most-read Content of October: All-cause Excess Mortality, SGLT2 Inhibitors & Drug Safety Regulatory Response
Recent developments from the Section of Cardiovascular Medicine.
- October 13, 2022
Guideline-directed medical therapies are under-utilized. Two trainees developed an interactive consult tool to provide guidance at each stage of kidney disease.
- October 06, 2022
Most-read Content of September: Using risk scores to improve patient outcomes, dual antiplatelet therapy, and more
The Section of Cardiovascular Medicine published research in American Heart Journal, JAMA Internal Medicine, and JAMA Cardiology.
- September 26, 2022
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific MeetingSource: Yahoo
The Heart Failure Society of America (HFSA) Annual Scientific Meeting will take place in Washington, D.C. from September 30, 2022 to October 3, 2022.
- August 21, 2022Source: ReachMD Radio
The Pragmatic Trial of Messaging to Providers About Treatment in Heart Failure (PROMPT-HF) was designed to test the hypothesis that tailored and targeted electronic health record alerts recommending guideline-directed medical therapy (GDMT) for patients with heart failure (HF) would result in greater adherence to medication use.
- August 18, 2022Source: Healio
An embedded electronic health record algorithm that provided HF mortality risk information did not affect clinical decision making about initiation or intensity of treatment or improve outcomes in adults with HF, data show.
- August 17, 2022
Late-Breaking Basic Science submissions for the AHA Scientific Sessions close August 23.
- August 13, 2022
Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trialSource: 2minutemedicine
No significant differences in targeted interventions occurred between patients with heart failure managed by clinicians with additional prognostic information compared to those without.
- August 10, 2022Source: AJMC
The REVEAL-HF study investigated using risk scores to improve patient outcomes through targeted interventions, including treatment initiation and intensity, end-of-life care, and hospitalization and mortality risks.